Royalty Report: Drugs, Cancer, Therapeutic – Collection: 381105

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Disease
  • Drug Discovery
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 381105

License Grant
Bermuda Licensor hereby grants to Swiss Licensee and its Affiliates and its Sublicensees, access to, and a right of reference with respect to, any Licensor Regulatory Materials and corresponding documentation to the extent Controlled by Licensor at any time during the Term, solely for the purposes of (a) Exploiting the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Field in the Licensee Territory, (b) Manufacturing the Licensed Compounds and Licensed Products, (c) completing the On-Going Clinical Trials and (d) performing Licensee’s obligations under this Agreement with respect to the Licensed Compounds and Licensed Products in the Field in the Licensor Territory.
License Property
Licensed Product means any TAK-385 Licensed Product or TAK-448 Licensed Product.

TAK-385 Licensed Product means any pharmaceutical product, including all forms, presentations, strengths, doses, and formulations (including any method of delivery) containing a TAK-385 Licensed Compound.

TAK-448 Licensed Product means any pharmaceutical product, including all forms, presentations, strengths, doses, and formulations (including any method of delivery) containing a TAK-448 Licensed Compound.

Licensed Compound means a TAK-385 Licensed Compound or a TAK-448 Licensed Compound.

TAK-385 Licensed Compound means (a) the chemical compound coded by Licensee as TAK-385 and the structure of which is set forth in Agreement (TAK-385 Licensed Compound); (b) any compound other than TAK-385 that is Covered by any Licensee Patent Right set forth in Agreement (Licensee Patent Rights) that also Covers TAK-385; and (c) any radioisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, ester forms or prodrugs of any compound described in clause (a).

TAK-448 Licensed Compound means (a) the oligopeptide coded by Licensee as TAK-448 and the structure of which is set forth in Agreement (TAK-448 Licensed Compound); (c) any oligopeptide other than TAK-448 that is Covered by any Licensee Patent Right set forth in Agreement (Licensee Patent Rights) that also Covers TAK-448; and (d) any radioisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, ester forms or prodrugs of any compound described in clause (a).

Licensee Patent Rights means (a) those Patent Rights set forth in Agreement part (a) (TAK-385 Patent Rights), (b) those Patent Rights set forth in Agreement part (b) (TAK-448 Patent Rights), and (c) all Patent Rights (other than Licensor Patent Rights and Joint Patent Rights) Controlled by Licensee during the Term that Cover any Invention made by or on behalf of Licensee after the Effective Date that Covers a Licensed Compound or any Licensed Product or is otherwise necessary to Exploit any Licensed Compound or Licensed Product.

Field of Use
Field means the treatment, prevention, cure, or control of any human disease, disorder, illness, or condition, including the Men’s Health Field and the Women’s Health Field.

Men’s Health Field means the treatment, prevention, cure, or control of symptoms associated with prostate cancer.

Women’s Health Field means the treatment, prevention, cure, or control of symptoms associated with Uterine Fibroids or Endometriosis.

Uterine fibroids, also known as uterine leiomyomas or fibroids, are benign smooth muscle tumors of the uterus.
Endometriosis is a disease of the female reproductive system in which cells similar to those in the endometrium, the layer of tissue that normally covers the inside of the uterus, grow outside the uterus.

relugolix (TAK-385) is a phase 3 drug candidate that has been evaluated in over 1,300 patients to date. Relugolix has successfully demonstrated significant clinical benefit and was generally well-tolerated across multiple, large, randomized phase 2 clinical trials in three different indications. Relugolix is being developed as an oral, once-daily, potential best-in-class gonadotropin-releasing hormone (GnRH) receptor antagonist for uterine fibroids, endometriosis and prostate cancer.

IPSCIO Record ID: 372427

License Grant
Swiss Licensor hereby grants to Bermuda Licensee an exclusive, sublicensable (Sublicensing), royalty-bearing right and license under the Licensor Technology and Licensor’s interest in the Joint Technology to Exploit the Licensed Compounds and Licensed Products in the Field in the Licensee Territory.

Licensor hereby grants to Licensee a non-exclusive, sublicensable (Sublicensing) right and license under the Licensor Technology and Licensor’s interest in the Joint Technology to (a) Develop the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Men’s Health Field in the Licensor Territory solely for the purpose of Exploiting such Licensed Products in the Field in the Licensee Territory, or as required in order for Licensee to comply with its diligence obligations set forth in Agreement (Development Diligence Obligations) and (b) Manufacture the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Licensor Territory.

Licensor hereby grants to Licensee (or its Affiliates or its Sublicensees) access to, and a right of reference with respect to, any Licensor Regulatory Materials and corresponding documentation to the extent Controlled by Licensor at any time during the Term, solely for the purposes of (a) Exploiting the Licensed Compounds and Licensed Products in the Field in the Licensee Territory, (b) Developing the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Men’s Health Field in the Licensor Territory, and (c) Manufacturing the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Licensor Territory.

License Property
Licensed Product means any TAK-385 Licensed Product or TAK-448 Licensed Product.

TAK-385 Licensed Product means any pharmaceutical product, including all forms, presentations, strengths, doses, and formulations (including any method of delivery) containing a TAK-385 Licensed Compound.

TAK-448 Licensed Product means any pharmaceutical product, including all forms, presentations, strengths, doses, and formulations (including any method of delivery) containing a TAK-448 Licensed Compound.

Licensed Compound means a TAK-385 Licensed Compound or a TAK-448 Licensed Compound.

TAK-385 Licensed Compound means (a) the chemical compound coded by Licensor as TAK-385 and the structure of which is set forth in Agreement (TAK-385 Licensed Compound); (b) any compound other than TAK-385 that is Covered by any Licensor Patent Right set forth in Agreement (Licensor Patent Rights) that also Covers TAK-385; and (c) any radioisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, ester forms or prodrugs of any compound described in clause (a).

TAK-448 Licensed Compound means (a) the oligopeptide coded by Licensor as TAK-448 and the structure of which is set forth in Agreement (TAK-448 Licensed Compound); (c) any oligopeptide other than TAK-448 that is Covered by any Licensor Patent Right set forth in Agreement (Licensor Patent Rights) that also Covers TAK-448; and (d) any radioisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, ester forms or prodrugs of any compound described in clause (a).

Licensor Patent Rights means (a) those Patent Rights set forth in Agreement part (a) (TAK-385 Patent Rights), (b) those Patent Rights set forth in Agreement part (b) (TAK-448 Patent Rights), and (c) all Patent Rights (other than Licensee Patent Rights and Joint Patent Rights) Controlled by Licensor during the Term that Cover any Invention made by or on behalf of Licensor after the Effective Date that Covers a Licensed Compound or any Licensed Product or is otherwise necessary to Exploit any Licensed Compound or Licensed Product.

Field of Use
Field means the treatment, prevention, cure, or control of any human disease, disorder, illness, or condition, including the Men’s Health Field and the Women’s Health Field.

Men’s Health Field means the treatment, prevention, cure, or control of symptoms associated with prostate cancer.

Women’s Health Field means the treatment, prevention, cure, or control of symptoms associated with Uterine Fibroids or Endometriosis.

IPSCIO Record ID: 359061

License Grant
Included with this license and collaboration agreement is a license grant upon voluntary termination.

With respect to the applicable Reversion Compounds being terminated, Licensor grants, effective upon such termination, an exclusive even us to Licensor. sub-licensable, worldwide license under the Licensor Reversion Technology to research, develop, import, use, make. have made, offer for sale and sell Reversion Compounds and Reversion Products including as part of a Licensee Combination Therapy in the Field in the Territory.

License Property
Licensors Reversion Technology means Licensor Technology that both was actually used or generated by Licensor or its Affiliates or Sublicensees with respect to the applicable Reversion Compound or Reversion Product, and is necessary to continue development, manufacture or commercialization without unreasonable delay of the applicable Reversion Compound or Reversion Product.

Reversion Compound means NLG919, any Next Generation Compound or any Subsequent Compound.

NLG919 means Licensee’s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.

Next Generation Compound means any Compound other than NLG919 that is invented, by or on behalf of Licensee or its Affiliate, whether solely or jointly, as of the Effective Date or thereafter during the Restriction Period, whether or not pursuant to the Research Plan, that is invented or otherwise the subject of research or preclinical development conducted, by or on behalf of Licensor or its Affiliate or Sublicensee, but excluding the pRED Organization, whether solely or jointly, during the Next Gen Research Term, whether or not pursuant to the Research Plan, the composition of matter, manufacture or use of which is Covered by a Valid Claim of a Licensee Patent or Collaboration Patent; or that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described above.

Field of Use
Field means any use.

Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.

IPSCIO Record ID: 344493

License Grant
Licensor of Germany grants an exclusive license to use Licensors Patent Rights and Licensors Know-How to develop, use, make, have made, sell, offer for sale, have sold, import and export, commercialize Contract Products and/or D-63153 in the Field and in the Territory. The license shall include the right to use Licensors Patent Rights and Know-How in conducting research and development activities with respect to the use of Contract Products and/or D-63153 in the Field and in the Territory.

Licensor grants a right of first negotiation to Licensee in case Licensee intends to license from Licensor any additional analogs which all under a valid claim of the LHRH Patents in the United States.

License Property
Contract Products shall mean and include all pharmaceutical products manufactured by Licensee, whether as mono-preparations or combination preparations, with the D63153 as an active ingredient, for use in the Field.

The active ingredient is referred to as ozarelix.  Ozarelix is a Luteinizing Hormone Releasing Hormone, or LHRH, antagonist (a substance that blocks the effects of a natural hormone found in the body). Mechanistically, LHRH antagonists exert rapid inhibition of luteinizing hormone and follicle stimulating hormone with an accompanying rapid decrease in sex hormones and would therefore be expected to be effective in a variety of hormonally dependent disease states including ovarian cancer, prostate cancer, BPH, infertility, uterine myoma and endometriosis.

LHRH Patents shall mean the composition in matter patents regarding a novel LHRH antagonist having improved solubility properties· with the internal No. 98/20 PH, the LHRH.

The patents are titled
— LHRH antagonists having improved solubility properties,
— Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof,
— Application of initial Doses of LHRH Analogues and Maintenance Doses of LHRH Antagonists for the Treatment of Hormone-dependent Cancers and Corresponding Pharmaceutical Kits, and,
— Use of LHRH Antagonists for intermittent Treatments.

Field of Use
The Initial indication shall mean the use of D-63153 and/or Contract Products for prostate cancer and benign prostate hyperplasia (BPH).

IPSCIO Record ID: 203285

License Grant
Licensor grants an exclusive, worldwide, non-transferable, license, with the right to sublicense, under the Licensor Patent Rights and Know-How to make, use, including in activities directed at the research and Development of Licensed Compounds, have made, sell, have sold, offer to sell, export, import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

Licensor grants a non-transferable, non-exclusive license, with the right to sublicense, under the Licensor Other Patent Rights solely to the extent reasonably necessary to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

License Property
MS564929 Toxicology Studies means the two (2) toxicology reports due n the IND covering the BMS compound designated BMS564929, specifically the 6 onth oral toxicology studies in rats and dogs.

6,670,386 – Bicyclic modulators of androgen receptor function

The licensed compounds and patents relate to controlling various diseases and cancers.

Field of Use
The Field means the diagnosis, prevention, treatment or control of any human or animal disease, disorder or condition, excluding the prevention, treatment or control of any human or animal hyperproliferative disease, disorder or condition. For purposes of clarity, hyperproliferative diseases, disorders and conditions are those diseases, disorders or conditions which are characterized by an abnormal increase in the proliferation or accumulation of cells and include conditions such as cancers and benign hyperplasia, but not diseases, disorders or conditions incident to an abnormal increase in the proliferation or accumulation of cells.

IPSCIO Record ID: 222534

License Grant
Licensor grants an exclusive license, or sublicense, as the case may be, under the Licensor Patent Rights and Know-how, in each case with the right to grant sublicenses, to research, develop, make, have made, use, import, export, market, offer for sale, sell and have sold, Licensed Product in the Territory within the applicable Field.
License Property
The Compounds means SCH 619734 (Rolapitant) and SCH 900978.

The Licensed Product means any product comprising, incorporating or containing any Compound, or an alternate form of any Compound, including, but not limited to, a pharmaceutically acceptable salt, polymorph, crystal form, prodrug, or solvate of any Compound to the extent such alternate form is claimed in the Licensor Patent Rights.

Rolapitant, a Phase III-ready, oncology supportive-care product candidate, is a potent and selective neurokinin-1 (NK-1) receptor antagonist with an extended plasma half-life that has the potential to improve the management of nausea and vomiting experienced by cancer patients undergoing treatment with emetogenic chemotherapy. Phase II clinical testing of rolapitant for the prevention of nausea and vomiting in cancer patients treated with highly emetogenic chemotherapy demonstrated promising five-day activity following the administration of a single dose.

Field of Use
The Field means with respect to SCH 619734 (Rolapitant) all therapeutic, prophylactic, palliative and diagnostic uses in humans, and means, with respect to SCH 900978, treatment of nausea or vomiting of any cause; treatment of disease or treatment of symptoms or side effects of disease in oncology indications; treatment of side effects of oncology treatments or therapies; and (iv) any other supportive care indications in oncology.

IPSCIO Record ID: 369278

License Grant
Licensor hereby grants to Licensee a royalty-bearing, non-transferable license, with the right to grant sublicenses as provided in Agreement, under the Licensor Technology and Licensor Trademarks, which license shall be non-exclusive with respect to the Merck Know-How and exclusive (even as to Licensor, except to the extent necessary for Licensor to perform its obligations under this Agreement with respect to any Licensor Technology (other than the Merck Know-How) and the Licensor Trademarks, to Exploit the Compounds and Products in the Licensee Field in the Licensee Territory.  The foregoing license grant by Licensor does not include any grant of rights under the Licensor Technology or Licensor Trademarks to Exploit any active pharmaceutical compound that is not a Compound, other than, to the extent applicable, any API(s) Controlled by Licensor (if any) that are included in a Product that is deemed to be a Single Agent Product pursuant to this Agreement.
License Property
Product means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations (including any method of delivery), containing a Compound alone or in combination with other APIs.  For the sake of clarity, all forms, presentations, doses and formulations of a pharmaceutical product containing a Compound shall be considered the same Product for purposes of this Agreement, so long as each form, presentation, dose and formulation contains the same Compound and same other APIs (and no other Compounds or other APIs).

Compound means (a) the Initial Compound; (b) the compound licensed to Licensor under the Merck License Agreement and known as MK-2512; or (c) with respect to both (a) and (b), any pharmaceutically acceptable salt, polymorph, crystal form, prodrug or solvate thereof.

Licensor Patents means all Patents Controlled by Licensor during the Term that are necessary or useful to Exploit the Compounds or Products in the Licensee Field in the Licensee Territory.  Licensor Patents include, as of the Effective Date, those Patents set forth in Exhibit 1.117, the Merck Patents and AstraZeneca Patents.    
US #8071623 – Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
US #8436185 – Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
US #8188084 – Pyridinone and pyridazinone derivatives as inhibitors of poly (ADP-ribose) polymerase (PARP)

Trademark means any word, name, symbol, colour, designation, slogan, catch phrase or device or any combination thereof used or intended to be used in commerce and indicating the source for a product or service, including any domain name, trademark, trade dress, brand mark, trade name, brand name, logo or business symbol, any registrations of any of the foregoing or any pending applications therefor.

Field of Use
The collaboration and license agreement focused on the development and commercialization of niraparib specifically for the treatment of prostate cancer. Niraparib is an oral, once daily, potent, and highly selective PARP inhibitor that is currently being evaluated in Phase 3 clinical trials for ovarian and breast cancer.

IPSCIO Record ID: 28618

License Grant
Licensor hereby grants to Swiss Licensee and its Affiliates an exclusive, royalty-bearing license in the Territory, with the right to sublicense, under Celgene Patent Rights, Licensor's interest in Joint Patent Rights and Know-How of Licensor to develop, make, have made, use, sell, offer for sale and import Products in all Fields of Use, and non-exclusive, non-transferable, royalty-free research license in the Territory under Licensor Patent Rights, Licensor's interest in Joint Patent Rights and Know-How of Licensor solely for the purpose of conducting research on Research Compounds, Active Compounds, Candidate Compounds, Final Selected Compounds and Back-Up Compounds in all Fields of Use; provided, however, that

Licensor and its Affiliates developed expertise and acquired proprietary rights related to selective estrogen receptor modulator compounds ('SERMS') which are selective for Estrogen Receptor ('ER')(alpha) ('ER(alpha)') in U2OS cells (the 'ER(alpha)SELECTIVITY'

License Property
SP500263  Series  shall mean  Licensor's  proprietary  compounds claimed in U.S. Patent Application  Serial No.  09/475,776
Field of Use
Additional Field shall mean the treatment, prevention and diagnosis of a disease or disorder, other than a disease or disorder within the Primary Field or the Oncology Field.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.